ID   IKKB_HUMAN              Reviewed;         756 AA.
AC   O14920; B4DZ30; B4E0U4; O75327;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   10-MAY-2017, entry version 193.
DE   RecName: Full=Inhibitor of nuclear factor kappa-B kinase subunit beta;
DE            Short=I-kappa-B-kinase beta;
DE            Short=IKK-B;
DE            Short=IKK-beta;
DE            Short=IkBKB;
DE            EC=2.7.11.10;
DE   AltName: Full=I-kappa-B kinase 2;
DE            Short=IKK2;
DE   AltName: Full=Nuclear factor NF-kappa-B inhibitor kinase beta;
DE            Short=NFKBIKB;
GN   Name=IKBKB; Synonyms=IKKB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-44;
RP   SER-177 AND SER-181.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9346484; DOI=10.1126/science.278.5339.860;
RA   Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L.,
RA   Li J.W., Young D.B., Barbosa M., Mann M., Manning A., Rao A.;
RT   "IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-
RT   kappaB activation.";
RL   Science 278:860-866(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-44.
RX   PubMed=9346485; DOI=10.1126/science.278.5339.866;
RA   Woronicz J.D., Gao X., Cao Z., Rothe M., Goeddel D.V.;
RT   "IkappaB kinase-beta: NF-kappaB activation and complex formation with
RT   IkappaB kinase-alpha and NIK.";
RL   Science 278:866-869(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Heart;
RX   PubMed=9813230; DOI=10.1016/S0378-1119(98)00462-4;
RA   Hu M.C.-T., Wang Y.-P.;
RT   "IkappaB kinase-alpha and -beta genes are coexpressed in adult and
RT   embryonic tissues but localized to different human chromosomes.";
RL   Gene 222:31-40(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND GENE MAPPING.
RX   PubMed=9763654;
RA   Shindo M., Nakano H., Sakon S., Yagita H., Mihara M., Okumura K.;
RT   "Assignment of IkappaB kinase beta (IKBKB) to human chromosome band
RT   8p12-->p11 by in situ hybridization.";
RL   Cytogenet. Cell Genet. 82:32-33(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 4).
RC   TISSUE=Testis, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT TRP-554.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 170-182 (ISOFORM 1), INACTIVATION BY YERSINIA YOPJ
RP   (MICROBIAL INFECTION), ACETYLATION AT THR-180 (MICROBIAL INFECTION),
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17116858; DOI=10.1073/pnas.0608995103;
RA   Mittal R., Peak-Chew S.Y., McMahon H.T.;
RT   "Acetylation of MEK2 and I kappa B kinase (IKK) activation loop
RT   residues by YopJ inhibits signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18574-18579(2006).
RN   [10]
RP   IKK PHOSPHORYLATION.
RX   PubMed=9819420; DOI=10.1128/MCB.18.12.7336;
RA   Nemoto S., DiDonato J.A., Lin A.;
RT   "Coordinate regulation of IkappaB kinases by mitogen-activated protein
RT   kinase kinase kinase 1 and NF-kappaB-inducing kinase.";
RL   Mol. Cell. Biol. 18:7336-7343(1998).
RN   [11]
RP   IDENTIFICATION IN A COMPLEX WITH CHUK; NFKBIA; RELA; IKBKAP AND
RP   MAP3K14.
RX   PubMed=9751059; DOI=10.1038/26254;
RA   Cohen L., Henzel W.J., Baeuerle P.A.;
RT   "IKAP is a scaffold protein of the IkappaB kinase complex.";
RL   Nature 395:292-296(1998).
RN   [12]
RP   INTERACTION WITH SQSTM1; PRKCZ AND PRKCI.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [13]
RP   PHOSPHORYLATION AT SER-177 AND SER-181.
RX   PubMed=10022904; DOI=10.1128/MCB.19.3.2180;
RA   Lallena M.J., Diaz-Meco M.T., Bren G., Paya C.V., Moscat J.;
RT   "Activation of IkappaB kinase beta by protein kinase C isoforms.";
RL   Mol. Cell. Biol. 19:2180-2188(1999).
RN   [14]
RP   PHOSPHORYLATION AT SER-177; SER-181; SER-670; SER-672; SER-675;
RP   SER-682; SER-689; SER-692; SER-695; SER-697; SER-705; SER-733; SER-740
RP   AND SER-750.
RX   PubMed=10195894; DOI=10.1126/science.284.5412.309;
RA   Delhase M., Hayakawa M., Chen Y., Karin M.;
RT   "Positive and negative regulation of IkappaB kinase activity through
RT   IKKbeta subunit phosphorylation.";
RL   Science 284:309-313(1999).
RN   [15]
RP   INTERACTION WITH EIF2AK2.
RX   PubMed=10848580; DOI=10.1128/MCB.20.13.4532-4542.2000;
RA   Bonnet M.C., Weil R., Dam E., Hovanessian A.G., Meurs E.F.;
RT   "PKR stimulates NF-kappaB irrespective of its kinase function by
RT   interacting with the IkappaB kinase complex.";
RL   Mol. Cell. Biol. 20:4532-4542(2000).
RN   [16]
RP   PHOSPHORYLATION AT SER-177 AND SER-181 BY TBK1, AND MUTAGENESIS OF
RP   177-SER--SER-181.
RX   PubMed=10783893; DOI=10.1038/35008109;
RA   Tojima Y., Fujimoto A., Delhase M., Chen Y., Hatakeyama S.,
RA   Nakayama K., Kaneko Y., Nimura Y., Motoyama N., Ikeda K., Karin M.,
RA   Nakanishi M.;
RT   "NAK is an IkappaB kinase-activating kinase.";
RL   Nature 404:778-782(2000).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF NFKB1.
RX   PubMed=11297557; DOI=10.1074/jbc.M101754200;
RA   Salmeron A., Janzen J., Soneji Y., Bump N., Kamens J., Allen H.,
RA   Ley S.C.;
RT   "Direct phosphorylation of NF-kappa B1 p105 by the Ikappa B kinase
RT   complex on serine 927 is essential for signal-induced p105
RT   proteolysis.";
RL   J. Biol. Chem. 276:22215-22222(2001).
RN   [18]
RP   INTERACTION WITH IKBKG AND TANK.
RX   PubMed=12133833; DOI=10.1074/jbc.M205069200;
RA   Chariot A., Leonardi A., Muller J., Bonif M., Brown K., Siebenlist U.;
RT   "Association of the adaptor TANK with the I kappa B kinase (IKK)
RT   regulator NEMO connects IKK complexes with IKK epsilon and TBK1
RT   kinases.";
RL   J. Biol. Chem. 277:37029-37036(2002).
RN   [19]
RP   IDENTIFICATION IN A COMPLEX WITH CREBBP; NCOA2; NCOA3; IKKA AND IKBKG.
RX   PubMed=11971985; DOI=10.1128/MCB.22.10.3549-3561.2002;
RA   Wu R.-C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator
RT   activity by I kappa B kinase.";
RL   Mol. Cell. Biol. 22:3549-3561(2002).
RN   [20]
RP   COMPOSITION OF THE IKK COMPLEX.
RX   PubMed=12612076; DOI=10.1128/MCB.23.6.2029-2041.2003;
RA   Tegethoff S., Behlke J., Scheidereit C.;
RT   "Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is
RT   obligatory for IKK complex activity and NF-kappaB activation.";
RL   Mol. Cell. Biol. 23:2029-2041(2003).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH FOXO3.
RX   PubMed=15084260; DOI=10.1016/S0092-8674(04)00302-2;
RA   Hu M.C., Lee D.F., Xia W., Golfman L.S., Ou-Yang F., Yang J.Y.,
RA   Zou Y., Bao S., Hanada N., Saso H., Kobayashi R., Hung M.C.;
RT   "IkappaB kinase promotes tumorigenesis through inhibition of forkhead
RT   FOXO3a.";
RL   Cell 117:225-237(2004).
RN   [22]
RP   INTERACTION WITH TICAM1.
RX   PubMed=14739303; DOI=10.1074/jbc.M311629200;
RA   Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.;
RT   "Mechanisms of the TRIF-induced interferon-stimulated response element
RT   and NF-kappaB activation and apoptosis pathways.";
RL   J. Biol. Chem. 279:15652-15661(2004).
RN   [23]
RP   INTERACTION WITH NALP2.
RX   PubMed=15456791; DOI=10.1074/jbc.M406741200;
RA   Bruey J.-M., Bruey-Sedano N., Newman R., Chandler S., Stehlik C.,
RA   Reed J.C.;
RT   "PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates
RT   NF-kappaB and caspase-1 activation in macrophages.";
RL   J. Biol. Chem. 279:51897-51907(2004).
RN   [24]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15173580; DOI=10.1073/pnas.0402851101;
RA   Witherow D.S., Garrison T.R., Miller W.E., Lefkowitz R.J.;
RT   "beta-Arrestin inhibits NF-kappaB activity by means of its interaction
RT   with the NF-kappaB inhibitor IkappaBalpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:8603-8607(2004).
RN   [25]
RP   S-NITROSYLATION AT CYS-179.
RX   PubMed=15184672; DOI=10.1073/pnas.0400588101;
RA   Reynaert N.L., Ckless K., Korn S.H., Vos N., Guala A.S., Wouters E.F.,
RA   van der Vliet A., Janssen-Heininger Y.M.;
RT   "Nitric oxide represses inhibitory kappaB kinase through S-
RT   nitrosylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:8945-8950(2004).
RN   [26]
RP   INTERACTION WITH NIBP.
RX   PubMed=15951441; DOI=10.1074/jbc.M501670200;
RA   Hu W.-H., Pendergast J.S., Mo X.-M., Brambilla R., Bracchi-Ricard V.,
RA   Li F., Walters W.M., Blits B., He L., Schaal S.M., Bethea J.R.;
RT   "NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-
RT   (kappa)B activation.";
RL   J. Biol. Chem. 280:29233-29241(2005).
RN   [27]
RP   PHOSPHORYLATION AT SER-181 BY PDPK1, AND INTERACTION WITH PDPK1.
RX   PubMed=16207722; DOI=10.1074/jbc.M506235200;
RA   Tanaka H., Fujita N., Tsuruo T.;
RT   "3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase
RT   beta (IkkB) phosphorylation activates NF-kappaB signaling.";
RL   J. Biol. Chem. 280:40965-40973(2005).
RN   [28]
RP   UBIQUITINATION AT LYS-163.
RX   PubMed=16267042; DOI=10.1074/jbc.M508656200;
RA   Carter R.S., Pennington K.N., Arrate P., Oltz E.M., Ballard D.W.;
RT   "Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates
RT   its phosphorylation and persistent activation.";
RL   J. Biol. Chem. 280:43272-43279(2005).
RN   [29]
RP   INTERACTION WITH MAVS.
RX   PubMed=16177806; DOI=10.1038/nature04193;
RA   Meylan E., Curran J., Hofmann K., Moradpour D., Binder M.,
RA   Bartenschlager R., Tschopp J.;
RT   "Cardif is an adaptor protein in the RIG-I antiviral pathway and is
RT   targeted by hepatitis C virus.";
RL   Nature 437:1167-1172(2005).
RN   [30]
RP   HYDROXYLATION AT PRO-191, AND MUTAGENESIS OF PRO-191.
RX   PubMed=17114296; DOI=10.1073/pnas.0602235103;
RA   Cummins E.P., Berra E., Comerford K.M., Ginouves A., Fitzgerald K.T.,
RA   Seeballuck F., Godson C., Nielsen J.E., Moynagh P., Pouyssegur J.,
RA   Taylor C.T.;
RT   "Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving
RT   insight into hypoxia-induced NFkappaB activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18154-18159(2006).
RN   [31]
RP   INTERACTION WITH YOPJ (MICROBIAL INFECTION), AND ACETYLATION
RP   (MICROBIAL INFECTION).
RX   PubMed=16728640; DOI=10.1126/science.1126867;
RA   Mukherjee S., Keitany G., Li Y., Wang Y., Ball H.L., Goldsmith E.J.,
RA   Orth K.;
RT   "Yersinia YopJ acetylates and inhibits kinase activation by blocking
RT   phosphorylation.";
RL   Science 312:1211-1214(2006).
RN   [32]
RP   INTERACTION WITH ATM.
RX   PubMed=16497931; DOI=10.1126/science.1121513;
RA   Wu Z.H., Shi Y., Tibbetts R.S., Miyamoto S.;
RT   "Molecular linkage between the kinase ATM and NF-kappaB signaling in
RT   response to genotoxic stimuli.";
RL   Science 311:1141-1146(2006).
RN   [33]
RP   IDENTIFICATION IN A MEMBRANE RAFT COMPLEX, AND SUBCELLULAR LOCATION.
RX   PubMed=17287217; DOI=10.1074/jbc.M609157200;
RA   Ohnuma K., Uchiyama M., Yamochi T., Nishibashi K., Hosono O.,
RA   Takahashi N., Kina S., Tanaka H., Lin X., Dang N.H., Morimoto C.;
RT   "Caveolin-1 triggers T-cell activation via CD26 in association with
RT   CARMA1.";
RL   J. Biol. Chem. 282:10117-10131(2007).
RN   [34]
RP   INTERACTION WITH FAF1.
RX   PubMed=17684021; DOI=10.1074/jbc.C700106200;
RA   Park M.Y., Moon J.H., Lee K.S., Choi H.I., Chung J., Hong H.J.,
RA   Kim E.;
RT   "FAF1 suppresses IkappaB kinase (IKK) activation by disrupting the IKK
RT   complex assembly.";
RL   J. Biol. Chem. 282:27572-27577(2007).
RN   [35]
RP   FUNCTION IN PHOSPHORYLATION OF BCL10.
RX   PubMed=17213322; DOI=10.1073/pnas.0606982104;
RA   Lobry C., Lopez T., Israel A., Weil R.;
RT   "Negative feedback loop in T cell activation through IkappaB kinase-
RT   induced phosphorylation and degradation of Bcl10.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:908-913(2007).
RN   [36]
RP   REVIEW.
RX   PubMed=10712233;
RA   Jobin C., Sartor R.B.;
RT   "The I kappa B/NF-kappa B system: a key determinant of mucosal
RT   inflammation and protection.";
RL   Am. J. Physiol. 278:C451-C462(2000).
RN   [37]
RP   REVIEW, AND DOMAIN.
RX   PubMed=18626576; DOI=10.1007/s12026-008-8025-1;
RA   Solt L.A., May M.J.;
RT   "The IkappaB kinase complex: master regulator of NF-kappaB
RT   signaling.";
RL   Immunol. Res. 42:3-18(2008).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-672, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [41]
RP   INTERACTION WITH NAA10, AND FUNCTION IN PHOSPHORYLATION OF NAA10.
RX   PubMed=19716809; DOI=10.1016/j.bbrc.2009.08.127;
RA   Kuo H.P., Lee D.F., Xia W., Lai C.C., Li L.Y., Hung M.C.;
RT   "Phosphorylation of ARD1 by IKKbeta contributes to its destabilization
RT   and degradation.";
RL   Biochem. Biophys. Res. Commun. 389:156-161(2009).
RN   [42]
RP   DEPHOSPHORYLATION AT SER-177 AND SER-181, AND INTERACTION WITH PPM1A
RP   AND PPM1B.
RX   PubMed=18930133; DOI=10.1016/j.cellsig.2008.09.012;
RA   Sun W., Yu Y., Dotti G., Shen T., Tan X., Savoldo B., Pass A.K.,
RA   Chu M., Zhang D., Lu X., Fu S., Lin X., Yang J.;
RT   "PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-
RT   induced IKKbeta-NF-kappaB activation.";
RL   Cell. Signal. 21:95-102(2009).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-672, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [45]
RP   FUNCTION, AND INTERACTION WITH NLRC5.
RX   PubMed=20434986; DOI=10.1016/j.cell.2010.03.040;
RA   Cui J., Zhu L., Xia X., Wang H.Y., Legras X., Hong J., Ji J., Shen P.,
RA   Zheng S., Chen Z.J., Wang R.F.;
RT   "NLRC5 negatively regulates the NF-kappaB and type I interferon
RT   signaling pathways.";
RL   Cell 141:483-496(2010).
RN   [46]
RP   INTERACTION WITH TRIM21, MONOUBIQUITINATION, UBIQUITINATION
RP   INACTIVATION BY YERSINIA YOPJ (MICROBIAL INFECTION), AND MUTAGENESIS
RP   OF LYS-163; SER-177 AND SER-181.
RX   PubMed=19675099; DOI=10.1093/jb/mvp127;
RA   Wada K., Niida M., Tanaka M., Kamitani T.;
RT   "Ro52-mediated monoubiquitination of IKK{beta} down-regulates
RT   NF-{kappa}B signalling.";
RL   J. Biochem. 146:821-832(2009).
RN   [47]
RP   FUNCTION IN PHOSPHORYLATION OF RELA.
RX   PubMed=20410276; DOI=10.1128/JVI.00142-10;
RA   Yoboua F., Martel A., Duval A., Mukawera E., Grandvaux N.;
RT   "Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation
RT   at serine 536 is dependent on RIG-I, TRAF6, and IKK beta.";
RL   J. Virol. 84:7267-7277(2010).
RN   [48]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=20797629; DOI=10.1016/j.molcel.2010.07.030;
RA   Tsuchiya Y., Asano T., Nakayama K., Kato T. Jr., Karin M., Kamata H.;
RT   "Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination
RT   and degradation in UV-induced NF-kappaB activation.";
RL   Mol. Cell 39:570-582(2010).
RN   [49]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [50]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [51]
RP   FUNCTION, AND PHOSPHORYLATION BY TBK1 AND IKBKE.
RX   PubMed=21138416; DOI=10.1042/BJ20101701;
RA   Clark K., Peggie M., Plater L., Sorcek R.J., Young E.R., Madwed J.B.,
RA   Hough J., McIver E.G., Cohen P.;
RT   "Novel cross-talk within the IKK family controls innate immunity.";
RL   Biochem. J. 434:93-104(2011).
RN   [52]
RP   INTERACTION WITH ZNF268, AND SUBUNIT.
RX   PubMed=23091055; DOI=10.1074/jbc.M112.399923;
RA   Wang W., Guo M., Hu L., Cai J., Zeng Y., Luo J., Shu Z., Li W.,
RA   Huang Z.;
RT   "The zinc finger protein ZNF268 is overexpressed in human cervical
RT   cancer and contributes to tumorigenesis via enhancing NF-kappaB
RT   signaling.";
RL   J. Biol. Chem. 287:42856-42866(2012).
RN   [53]
RP   INTERACTION WITH IKBKE.
RX   PubMed=23453969; DOI=10.1016/j.celrep.2013.01.031;
RA   Zhou A.Y., Shen R.R., Kim E., Lock Y.J., Xu M., Chen Z.J., Hahn W.C.;
RT   "IKKepsilon-mediated tumorigenesis requires K63-linked
RT   polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase
RT   complex.";
RL   Cell Rep. 3:724-733(2013).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-672 AND SER-675, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [55]
RP   INTERACTION WITH AKAP13.
RX   PubMed=23090968; DOI=10.1128/MCB.00887-12;
RA   del Vescovo C.D., Cotecchia S., Diviani D.;
RT   "A-kinase-anchoring protein-Lbc anchors IkappaB kinase beta to support
RT   interleukin-6-mediated cardiomyocyte hypertrophy.";
RL   Mol. Cell. Biol. 33:14-27(2013).
RN   [56]
RP   INVOLVEMENT IN IMD15.
RX   PubMed=24369075; DOI=10.1056/NEJMoa1309199;
RA   Pannicke U., Baumann B., Fuchs S., Henneke P., Rensing-Ehl A.,
RA   Rizzi M., Janda A., Hese K., Schlesier M., Holzmann K., Borte S.,
RA   Laux C., Rump E.M., Rosenberg A., Zelinski T., Schrezenmeier H.,
RA   Wirth T., Ehl S., Schroeder M.L., Schwarz K.;
RT   "Deficiency of innate and acquired immunity caused by an IKBKB
RT   mutation.";
RL   N. Engl. J. Med. 369:2504-2514(2013).
RN   [57]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-675, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [58]
RP   INTERACTION WITH IFIT5.
RX   PubMed=26334375; DOI=10.1016/j.cellsig.2015.08.018;
RA   Zheng C., Zheng Z., Zhang Z., Meng J., Liu Y., Ke X., Hu Q., Wang H.;
RT   "IFIT5 positively regulates NF-kappaB signaling through synergizing
RT   the recruitment of IkappaB kinase (IKK) to TGF-beta-activated kinase 1
RT   (TAK1).";
RL   Cell. Signal. 27:2343-2354(2015).
RN   [59]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 701-742.
RX   PubMed=18462684; DOI=10.1016/j.str.2008.02.012;
RA   Rushe M., Silvian L., Bixler S., Chen L.L., Cheung A., Bowes S.,
RA   Cuervo H., Berkowitz S., Zheng T., Guckian K., Pellegrini M.,
RA   Lugovskoy A.;
RT   "Structure of a NEMO/IKK-associating domain reveals architecture of
RT   the interaction site.";
RL   Structure 16:798-808(2008).
RN   [61]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-360.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [62]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-360; ARG-369; GLN-526; THR-710 AND
RP   LEU-734.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine kinase that plays an essential role in the NF-
CC       kappa-B signaling pathway which is activated by multiple stimuli
CC       such as inflammatory cytokines, bacterial or viral products, DNA
CC       damages or other cellular stresses. Acts as part of the canonical
CC       IKK complex in the conventional pathway of NF-kappa-B activation
CC       and phosphorylates inhibitors of NF-kappa-B on 2 critical serine
CC       residues. These modifications allow polyubiquitination of the
CC       inhibitors and subsequent degradation by the proteasome. In turn,
CC       free NF-kappa-B is translocated into the nucleus and activates the
CC       transcription of hundreds of genes involved in immune response,
CC       growth control, or protection against apoptosis. In addition to
CC       the NF-kappa-B inhibitors, phosphorylates several other components
CC       of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits
CC       RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE.
CC       IKK-related kinase phosphorylations may prevent the overproduction
CC       of inflammatory mediators since they exert a negative regulation
CC       on canonical IKKs. Phosphorylates FOXO3, mediating the TNF-
CC       dependent inactivation of this pro-apoptotic transcription factor.
CC       Also phosphorylates other substrates including NCOA3, BCL10 and
CC       IRS1. Within the nucleus, acts as an adapter protein for NFKBIA
CC       degradation in UV-induced NF-kappa-B activation.
CC       {ECO:0000269|PubMed:11297557, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:17213322, ECO:0000269|PubMed:19716809,
CC       ECO:0000269|PubMed:20410276, ECO:0000269|PubMed:20434986,
CC       ECO:0000269|PubMed:20797629, ECO:0000269|PubMed:21138416}.
CC   -!- CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-B
CC       phosphoprotein].
CC   -!- SUBUNIT: Component of the I-kappa-B-kinase (IKK) core complex
CC       consisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-
CC       beta/IKBKB dimers are associated with four gamma/IKBKG subunits.
CC       The IKK core complex seems to associate with regulatory or adapter
CC       proteins to form a IKK-signalosome holo-complex (PubMed:12612076).
CC       The IKK complex associates with TERF2IP/RAP1, leading to promote
CC       IKK-mediated phosphorylation of RELA/p65 (By similarity). Part of
CC       a complex composed of NCOA2, NCOA3, CHUK/IKKA, IKBKB, IKBKG and
CC       CREBBP (PubMed:11971985). Part of a 70-90 kDa complex at least
CC       consisting of CHUK/IKKA, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14
CC       (PubMed:9751059). Found in a membrane raft complex, at least
CC       composed of BCL10, CARD11, DPP4 and IKBKB (PubMed:17287217).
CC       Interacts with SQSTM1 through PRKCZ or PRKCI (PubMed:10356400).
CC       Forms an NGF-induced complex with IKBKB, PRKCI and TRAF6 (By
CC       similarity). May interact with MAVS/IPS1 (PubMed:16177806).
CC       Interacts with NALP2 (PubMed:15456791). Interacts with TICAM1
CC       (PubMed:14739303). Interacts with FAF1; the interaction disrupts
CC       the IKK complex formation (PubMed:17684021). Interacts with ATM
CC       (PubMed:16497931). Part of a ternary complex consisting of TANK,
CC       IKBKB and IKBKG (PubMed:12133833). Interacts with NIBP; the
CC       interaction is direct (PubMed:15951441). Interacts with ARRB1 and
CC       ARRB2 (PubMed:15173580). Interacts with TRIM21 (PubMed:19675099).
CC       Interacts with NLRC5; prevents IKBKB phosphorylation and kinase
CC       activity (PubMed:20434986). Interacts with PDPK1
CC       (PubMed:16207722). Interacts with EIF2AK2/PKR (PubMed:10848580).
CC       The phosphorylated form interacts with PPM1A and PPM1B
CC       (PubMed:18930133). Interacts with ZNF268 isoform 2; the
CC       interaction is further increased in a TNF-alpha-dependent manner
CC       (PubMed:23091055). Interacts with IKBKE (PubMed:23453969).
CC       Interacts with NAA10, leading to NAA10 degradation
CC       (PubMed:19716809). Interacts with FOXO3 (PubMed:15084260).
CC       Interacts with AKAP13 (PubMed:23090968). Interacts with IFIT5; the
CC       interaction synergizes the recruitment of IKK to MAP3K7 and
CC       enhances IKK phosphorylation (PubMed:26334375).
CC       {ECO:0000250|UniProtKB:O88351, ECO:0000250|UniProtKB:Q9QY78,
CC       ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:10848580,
CC       ECO:0000269|PubMed:11971985, ECO:0000269|PubMed:12133833,
CC       ECO:0000269|PubMed:12612076, ECO:0000269|PubMed:14739303,
CC       ECO:0000269|PubMed:15084260, ECO:0000269|PubMed:15173580,
CC       ECO:0000269|PubMed:15456791, ECO:0000269|PubMed:15951441,
CC       ECO:0000269|PubMed:16177806, ECO:0000269|PubMed:16207722,
CC       ECO:0000269|PubMed:16497931, ECO:0000269|PubMed:17287217,
CC       ECO:0000269|PubMed:17684021, ECO:0000269|PubMed:18930133,
CC       ECO:0000269|PubMed:19675099, ECO:0000269|PubMed:19716809,
CC       ECO:0000269|PubMed:20434986, ECO:0000269|PubMed:23091055,
CC       ECO:0000269|PubMed:23453969, ECO:0000269|PubMed:26334375,
CC       ECO:0000269|PubMed:9751059}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Yersinia yopJ.
CC       {ECO:0000269|PubMed:16728640}.
CC   -!- INTERACTION:
CC       Q16543:CDC37; NbExp=4; IntAct=EBI-81266, EBI-295634;
CC       O15111:CHUK; NbExp=15; IntAct=EBI-81266, EBI-81249;
CC       Q92793:CREBBP; NbExp=2; IntAct=EBI-81266, EBI-81215;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-81266, EBI-352572;
CC       Q9Y6K9:IKBKG; NbExp=28; IntAct=EBI-81266, EBI-81279;
CC       Q14145:KEAP1; NbExp=6; IntAct=EBI-81266, EBI-751001;
CC       Q99558:MAP3K14; NbExp=3; IntAct=EBI-81266, EBI-358011;
CC       Q9Y6Q9:NCOA3; NbExp=3; IntAct=EBI-81266, EBI-81196;
CC       P19838:NFKB1; NbExp=3; IntAct=EBI-81266, EBI-300010;
CC       P25963:NFKBIA; NbExp=20; IntAct=EBI-81266, EBI-307386;
CC       P67775:PPP2CA; NbExp=3; IntAct=EBI-81266, EBI-712311;
CC       Q04206:RELA; NbExp=2; IntAct=EBI-81266, EBI-73886;
CC       P23396:RPS3; NbExp=4; IntAct=EBI-81266, EBI-351193;
CC       Q9UGK3:STAP2; NbExp=7; IntAct=EBI-81266, EBI-1553984;
CC       P03409:tax (xeno); NbExp=3; IntAct=EBI-81266, EBI-5236464;
CC       Q92574:TSC1; NbExp=3; IntAct=EBI-81266, EBI-1047085;
CC       P24772:VACWR196 (xeno); NbExp=3; IntAct=EBI-81266, EBI-4291651;
CC       Q5D1E7:Zc3h12a (xeno); NbExp=4; IntAct=EBI-81266, EBI-5326026;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20797629}.
CC       Nucleus {ECO:0000269|PubMed:20797629}. Membrane raft
CC       {ECO:0000269|PubMed:17287217}. Note=Colocalized with DPP4 in
CC       membrane rafts. {ECO:0000269|PubMed:17287217}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O14920-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14920-2; Sequence=VSP_041825;
CC       Name=3;
CC         IsoId=O14920-3; Sequence=VSP_041826, VSP_041827;
CC       Name=4;
CC         IsoId=O14920-4; Sequence=VSP_043408;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, placenta, skeletal
CC       muscle, kidney, pancreas, spleen, thymus, prostate, testis and
CC       peripheral blood.
CC   -!- DOMAIN: The kinase domain is located in the N-terminal region. The
CC       leucine zipper is important to allow homo- and hetero-
CC       dimerization. At the C-terminal region is located the region
CC       responsible for the interaction with NEMO/IKBKG.
CC       {ECO:0000269|PubMed:18626576}.
CC   -!- PTM: Upon cytokine stimulation, phosphorylated on Ser-177 and Ser-
CC       181 by MEKK1 and/or MAP3K14/NIK as well as TBK1 and PRKCZ; which
CC       enhances activity. Once activated, autophosphorylates on the C-
CC       terminal serine cluster; which decreases activity and prevents
CC       prolonged activation of the inflammatory response. Phosphorylated
CC       by the IKK-related kinases TBK1 and IKBKE, which is associated
CC       with reduced CHUK/IKKA and IKBKB activity and NF-kappa-B-dependent
CC       gene transcription. Dephosphorylated at Ser-177 and Ser-181 by
CC       PPM1A and PPM1B. {ECO:0000269|PubMed:10022904,
CC       ECO:0000269|PubMed:10195894, ECO:0000269|PubMed:10783893,
CC       ECO:0000269|PubMed:16207722}.
CC   -!- PTM: (Microbial infection) Acetylation of Thr-180 by Yersinia yopJ
CC       prevents phosphorylation and activation, thus blocking the I-
CC       kappa-B pathway. {ECO:0000269|PubMed:16728640,
CC       ECO:0000269|PubMed:17116858}.
CC   -!- PTM: Ubiquitinated. Monoubiquitination involves TRIM21 that leads
CC       to inhibition of Tax-induced NF-kappa-B signaling. According to
CC       PubMed:19675099, 'Ser-163' does not serve as a monoubiquitination
CC       site. According to PubMed:16267042, ubiquitination on 'Ser-163'
CC       modulates phosphorylation on C-terminal serine residues.
CC       {ECO:0000269|PubMed:16267042, ECO:0000269|PubMed:19675099}.
CC   -!- PTM: (Microbial infection) Monoubiquitination by TRIM21 is
CC       disrupted by Yersinia yopJ. {ECO:0000269|PubMed:19675099}.
CC   -!- PTM: Hydroxylated by PHD1/EGLN2, loss of hydroxylation under
CC       hypoxic conditions results in activation of NF-kappa-B.
CC       {ECO:0000269|PubMed:17114296}.
CC   -!- DISEASE: Immunodeficiency 15 (IMD15) [MIM:615592]: An autosomal
CC       recessive primary immunodeficiency disorder characterized by onset
CC       in infancy of life-threatening bacterial, fungal, and viral
CC       infections and failure to thrive. Laboratory studies show hypo- or
CC       agammaglobulinemia with relatively normal numbers of B and T-
CC       cells, and impaired differentiation and activation of immune
CC       cells. {ECO:0000269|PubMed:24369075}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. I-kappa-B kinase subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ikbkb/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF029684; AAC51860.1; -; mRNA.
DR   EMBL; AF080158; AAD08997.1; -; mRNA.
DR   EMBL; AF031416; AAC64675.1; -; mRNA.
DR   EMBL; AK302723; BAG63942.1; -; mRNA.
DR   EMBL; AK303528; BAG64556.1; -; mRNA.
DR   EMBL; AK316418; BAH14789.1; -; mRNA.
DR   EMBL; AY663108; AAT65965.1; -; Genomic_DNA.
DR   EMBL; AC083973; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006231; AAH06231.1; -; mRNA.
DR   CCDS; CCDS55228.1; -. [O14920-2]
DR   CCDS; CCDS56535.1; -. [O14920-4]
DR   CCDS; CCDS6128.1; -. [O14920-1]
DR   RefSeq; NP_001177649.1; NM_001190720.2. [O14920-2]
DR   RefSeq; NP_001229707.1; NM_001242778.1. [O14920-4]
DR   RefSeq; NP_001547.1; NM_001556.2. [O14920-1]
DR   UniGene; Hs.597664; -.
DR   PDB; 3BRT; X-ray; 2.25 A; A/C=701-730.
DR   PDB; 3BRV; X-ray; 2.20 A; A/C=701-745.
DR   PDB; 4E3C; X-ray; 3.98 A; A/B/C/D/E/F=11-669.
DR   PDB; 4KIK; X-ray; 2.83 A; A/B=2-664.
DR   PDBsum; 3BRT; -.
DR   PDBsum; 3BRV; -.
DR   PDBsum; 4E3C; -.
DR   PDBsum; 4KIK; -.
DR   ProteinModelPortal; O14920; -.
DR   SMR; O14920; -.
DR   BioGrid; 109767; 137.
DR   DIP; DIP-27527N; -.
DR   IntAct; O14920; 65.
DR   MINT; MINT-107608; -.
DR   STRING; 9606.ENSP00000430684; -.
DR   BindingDB; O14920; -.
DR   ChEMBL; CHEMBL1991; -.
DR   DrugBank; DB06151; Acetylcysteine.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   DrugBank; DB00995; Auranofin.
DR   DrugBank; DB00244; Mesalazine.
DR   DrugBank; DB05183; MLN0415.
DR   DrugBank; DB00795; Sulfasalazine.
DR   GuidetoPHARMACOLOGY; 2039; -.
DR   iPTMnet; O14920; -.
DR   PhosphoSitePlus; O14920; -.
DR   BioMuta; IKBKB; -.
DR   EPD; O14920; -.
DR   MaxQB; O14920; -.
DR   PaxDb; O14920; -.
DR   PeptideAtlas; O14920; -.
DR   PRIDE; O14920; -.
DR   DNASU; 3551; -.
DR   Ensembl; ENST00000416505; ENSP00000404920; ENSG00000104365. [O14920-4]
DR   Ensembl; ENST00000519735; ENSP00000430483; ENSG00000104365. [O14920-3]
DR   Ensembl; ENST00000520810; ENSP00000430684; ENSG00000104365. [O14920-1]
DR   Ensembl; ENST00000520835; ENSP00000430868; ENSG00000104365. [O14920-2]
DR   GeneID; 3551; -.
DR   KEGG; hsa:3551; -.
DR   UCSC; uc003xow.3; human. [O14920-1]
DR   CTD; 3551; -.
DR   DisGeNET; 3551; -.
DR   GeneCards; IKBKB; -.
DR   HGNC; HGNC:5960; IKBKB.
DR   HPA; CAB004447; -.
DR   HPA; HPA001249; -.
DR   MalaCards; IKBKB; -.
DR   MIM; 603258; gene.
DR   MIM; 615592; phenotype.
DR   neXtProt; NX_O14920; -.
DR   OpenTargets; ENSG00000104365; -.
DR   Orphanet; 397787; Severe combined immunodeficiency due to IKK2 deficiency.
DR   PharmGKB; PA29776; -.
DR   eggNOG; KOG4250; Eukaryota.
DR   eggNOG; ENOG410XRMU; LUCA.
DR   GeneTree; ENSGT00820000127009; -.
DR   HOGENOM; HOG000038048; -.
DR   HOVERGEN; HBG018241; -.
DR   InParanoid; O14920; -.
DR   KO; K07209; -.
DR   OMA; EVKFSSC; -.
DR   OrthoDB; EOG091G02VC; -.
DR   PhylomeDB; O14920; -.
DR   TreeFam; TF324269; -.
DR   BRENDA; 2.7.11.10; 2681.
DR   Reactome; R-HSA-1169091; Activation of NF-kappaB in B cells.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-209543; p75NTR recruits signalling complexes.
DR   Reactome; R-HSA-209560; NF-kB is activated and signals survival.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-446652; Interleukin-1 signaling.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5603027; IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR).
DR   Reactome; R-HSA-5603029; IkBA variant leads to EDA-ID.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10.
DR   Reactome; R-HSA-937039; IRAK1 recruits IKK complex.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   Reactome; R-HSA-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation.
DR   SABIO-RK; O14920; -.
DR   SignaLink; O14920; -.
DR   SIGNOR; O14920; -.
DR   ChiTaRS; IKBKB; human.
DR   EvolutionaryTrace; O14920; -.
DR   GeneWiki; IKK2; -.
DR   GenomeRNAi; 3551; -.
DR   PRO; PR:O14920; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000104365; -.
DR   CleanEx; HS_IKBKB; -.
DR   ExpressionAtlas; O14920; baseline and differential.
DR   Genevisible; O14920; HS.
DR   GO; GO:0035631; C:CD40 receptor complex; ISS:BHF-UCL.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0008385; C:IkappaB kinase complex; TAS:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008384; F:IkappaB kinase activity; TAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IDA:MGI.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0090002; P:establishment of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:1903347; P:negative regulation of bicellular tight junction assembly; IMP:UniProtKB.
DR   GO; GO:0035509; P:negative regulation of myosin-light-chain-phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1903140; P:regulation of establishment of endothelial barrier; IMP:UniProtKB.
DR   GO; GO:0042325; P:regulation of phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0009615; P:response to virus; TAS:UniProtKB.
DR   GO; GO:0042501; P:serine phosphorylation of STAT protein; IDA:UniProtKB.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IMP:UniProtKB.
DR   InterPro; IPR022007; IKKbetaNEMObind.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   InterPro; IPR000626; Ubiquitin_dom.
DR   Pfam; PF12179; IKKbetaNEMObind; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM01239; IKKbetaNEMObind; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Hydroxylation; Isopeptide bond; Kinase; Membrane; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   S-nitrosylation; SCID; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   CHAIN         1    756       Inhibitor of nuclear factor kappa-B
FT                                kinase subunit beta.
FT                                /FTId=PRO_0000086013.
FT   DOMAIN       15    300       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      21     29       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      458    479       Leucine-zipper.
FT   REGION      737    742       NEMO-binding.
FT   ACT_SITE    145    145       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      44     44       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     177    177       Phosphoserine; by TBK1 and PKC/PRKCZ.
FT                                {ECO:0000269|PubMed:10022904,
FT                                ECO:0000269|PubMed:10195894,
FT                                ECO:0000269|PubMed:10783893}.
FT   MOD_RES     179    179       S-nitrosocysteine.
FT                                {ECO:0000269|PubMed:15184672}.
FT   MOD_RES     180    180       O-acetylthreonine; by Yersinia yopJ.
FT                                {ECO:0000269|PubMed:17116858}.
FT   MOD_RES     181    181       Phosphoserine; by TBK1, PKC/PRKCZ and
FT                                PDPK1. {ECO:0000269|PubMed:10022904,
FT                                ECO:0000269|PubMed:10195894,
FT                                ECO:0000269|PubMed:10783893,
FT                                ECO:0000269|PubMed:16207722}.
FT   MOD_RES     191    191       Hydroxyproline.
FT                                {ECO:0000269|PubMed:17114296}.
FT   MOD_RES     670    670       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     672    672       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:10195894}.
FT   MOD_RES     675    675       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     675    675       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     682    682       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     689    689       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     692    692       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     695    695       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     697    697       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     705    705       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     733    733       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     740    740       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   MOD_RES     750    750       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:10195894}.
FT   CROSSLNK    163    163       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:16267042}.
FT   VAR_SEQ       1     66       MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQI
FT                                AIKQCRQELSPRNRERWCLEIQIMR -> MSSDGTI (in
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043408.
FT   VAR_SEQ       1     34       MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHN -> MFS
FT                                GGCHSPGFGRPSPAFPAPGSPPPAPRPCR (in isoform
FT                                2). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041825.
FT   VAR_SEQ     231    256       WHSKVRQKSEVDIVVSEDLNGTVKFS -> CVRMWPGTVAH
FT                                SCNPSTLGGRGRWIS (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041826.
FT   VAR_SEQ     257    756       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041827.
FT   VARIANT     360    360       A -> S (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_035626.
FT   VARIANT     369    369       Q -> R (in dbSNP:rs56411242).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040567.
FT   VARIANT     526    526       R -> Q (in dbSNP:rs2272736).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040568.
FT   VARIANT     554    554       R -> W (in dbSNP:rs17875749).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_021124.
FT   VARIANT     710    710       A -> T (in dbSNP:rs34309584).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040569.
FT   VARIANT     734    734       F -> L (in dbSNP:rs56301637).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040570.
FT   VARIANT     736    736       A -> T (in dbSNP:rs17611716).
FT                                /FTId=VAR_051628.
FT   MUTAGEN      44     44       K->A: Loss of kinase activity and no
FT                                effect on binding to NIK.
FT                                {ECO:0000269|PubMed:9346484,
FT                                ECO:0000269|PubMed:9346485}.
FT   MUTAGEN     163    163       K->R: Monoubiquitinated; when associated
FT                                with E-177 and E-181.
FT                                {ECO:0000269|PubMed:19675099}.
FT   MUTAGEN     177    181       SLCTS->ALCTA: COmplete loss of TBK1-
FT                                mediated phosphorylation.
FT                                {ECO:0000269|PubMed:10783893}.
FT   MUTAGEN     177    177       S->A: Decrease of activity.
FT                                {ECO:0000269|PubMed:19675099,
FT                                ECO:0000269|PubMed:9346484}.
FT   MUTAGEN     177    177       S->E: Full activation. Interaction with
FT                                TRIM21 is enhanced; when associated with
FT                                E-181. Monoubiquitinated; when associated
FT                                with R-163 and E-181. Strongly promoted
FT                                NF-kappa-B gene expression; when
FT                                associated with E-181.
FT                                {ECO:0000269|PubMed:19675099,
FT                                ECO:0000269|PubMed:9346484}.
FT   MUTAGEN     181    181       S->A: Decrease of activity.
FT                                {ECO:0000269|PubMed:19675099,
FT                                ECO:0000269|PubMed:9346484}.
FT   MUTAGEN     181    181       S->E: Full activation. Interaction with
FT                                TRIM21 is enhanced; when associated with
FT                                E-177. Monoubiquitinated; when associated
FT                                with R-163 and E-177. Strongly promoted
FT                                NF-kappa-B gene expression; when
FT                                associated with E-177.
FT                                {ECO:0000269|PubMed:19675099,
FT                                ECO:0000269|PubMed:9346484}.
FT   MUTAGEN     191    191       P->A: Loss of hypoxic inducibility.
FT                                {ECO:0000269|PubMed:17114296}.
FT   CONFLICT    259    259       L -> S (in Ref. 5; BAG63942/BAH14789).
FT                                {ECO:0000305}.
FT   STRAND       15     22       {ECO:0000244|PDB:4KIK}.
FT   STRAND       29     34       {ECO:0000244|PDB:4KIK}.
FT   TURN         35     37       {ECO:0000244|PDB:4KIK}.
FT   STRAND       40     44       {ECO:0000244|PDB:4KIK}.
FT   HELIX        52     67       {ECO:0000244|PDB:4KIK}.
FT   TURN         81     83       {ECO:0000244|PDB:4KIK}.
FT   HELIX        84     86       {ECO:0000244|PDB:4KIK}.
FT   STRAND       87     91       {ECO:0000244|PDB:4KIK}.
FT   STRAND       94     97       {ECO:0000244|PDB:4KIK}.
FT   HELIX       104    109       {ECO:0000244|PDB:4KIK}.
FT   HELIX       111    113       {ECO:0000244|PDB:4KIK}.
FT   HELIX       119    138       {ECO:0000244|PDB:4KIK}.
FT   HELIX       148    150       {ECO:0000244|PDB:4KIK}.
FT   STRAND      151    155       {ECO:0000244|PDB:4KIK}.
FT   STRAND      157    164       {ECO:0000244|PDB:4KIK}.
FT   HELIX       182    185       {ECO:0000244|PDB:4KIK}.
FT   TURN        186    188       {ECO:0000244|PDB:4KIK}.
FT   HELIX       191    195       {ECO:0000244|PDB:4KIK}.
FT   HELIX       202    217       {ECO:0000244|PDB:4KIK}.
FT   HELIX       228    235       {ECO:0000244|PDB:4KIK}.
FT   STRAND      244    247       {ECO:0000244|PDB:4KIK}.
FT   STRAND      253    258       {ECO:0000244|PDB:4KIK}.
FT   HELIX       267    280       {ECO:0000244|PDB:4KIK}.
FT   TURN        285    289       {ECO:0000244|PDB:4KIK}.
FT   TURN        292    294       {ECO:0000244|PDB:4KIK}.
FT   TURN        296    298       {ECO:0000244|PDB:4KIK}.
FT   HELIX       299    307       {ECO:0000244|PDB:4KIK}.
FT   STRAND      310    316       {ECO:0000244|PDB:4KIK}.
FT   TURN        317    320       {ECO:0000244|PDB:4KIK}.
FT   STRAND      321    327       {ECO:0000244|PDB:4KIK}.
FT   HELIX       333    344       {ECO:0000244|PDB:4KIK}.
FT   HELIX       348    350       {ECO:0000244|PDB:4KIK}.
FT   STRAND      353    355       {ECO:0000244|PDB:4KIK}.
FT   HELIX       367    370       {ECO:0000244|PDB:4KIK}.
FT   TURN        382    385       {ECO:0000244|PDB:4KIK}.
FT   STRAND      386    389       {ECO:0000244|PDB:4KIK}.
FT   HELIX       408    415       {ECO:0000244|PDB:4KIK}.
FT   HELIX       423    499       {ECO:0000244|PDB:4KIK}.
FT   TURN        500    504       {ECO:0000244|PDB:4KIK}.
FT   HELIX       509    520       {ECO:0000244|PDB:4KIK}.
FT   HELIX       527    548       {ECO:0000244|PDB:4KIK}.
FT   HELIX       559    575       {ECO:0000244|PDB:4KIK}.
FT   HELIX       579    581       {ECO:0000244|PDB:4KIK}.
FT   HELIX       588    661       {ECO:0000244|PDB:4KIK}.
FT   HELIX       706    729       {ECO:0000244|PDB:3BRV}.
FT   HELIX       734    736       {ECO:0000244|PDB:3BRV}.
FT   HELIX       740    742       {ECO:0000244|PDB:3BRV}.
SQ   SEQUENCE   756 AA;  86564 MW;  F9CADF671AE9E14E CRC64;
     MSWSPSLTTQ TCGAWEMKER LGTGGFGNVI RWHNQETGEQ IAIKQCRQEL SPRNRERWCL
     EIQIMRRLTH PNVVAARDVP EGMQNLAPND LPLLAMEYCQ GGDLRKYLNQ FENCCGLREG
     AILTLLSDIA SALRYLHENR IIHRDLKPEN IVLQQGEQRL IHKIIDLGYA KELDQGSLCT
     SFVGTLQYLA PELLEQQKYT VTVDYWSFGT LAFECITGFR PFLPNWQPVQ WHSKVRQKSE
     VDIVVSEDLN GTVKFSSSLP YPNNLNSVLA ERLEKWLQLM LMWHPRQRGT DPTYGPNGCF
     KALDDILNLK LVHILNMVTG TIHTYPVTED ESLQSLKARI QQDTGIPEED QELLQEAGLA
     LIPDKPATQC ISDGKLNEGH TLDMDLVFLF DNSKITYETQ ISPRPQPESV SCILQEPKRN
     LAFFQLRKVW GQVWHSIQTL KEDCNRLQQG QRAAMMNLLR NNSCLSKMKN SMASMSQQLK
     AKLDFFKTSI QIDLEKYSEQ TEFGITSDKL LLAWREMEQA VELCGRENEV KLLVERMMAL
     QTDIVDLQRS PMGRKQGGTL DDLEEQAREL YRRLREKPRD QRTEGDSQEM VRLLLQAIQS
     FEKKVRVIYT QLSKTVVCKQ KALELLPKVE EVVSLMNEDE KTVVRLQEKR QKELWNLLKI
     ACSKVRGPVS GSPDSMNASR LSQPGQLMSQ PSTASNSLPE PAKKSEELVA EAHNLCTLLE
     NAIQDTVREQ DQSFTALDWS WLQTEEEEHS CLEQAS
//
